The mission of the Partners Institutional Biosafety Committee (PIBC) is to promote safety and minimize the risks of performing biological research to Partners investigators, study participants, the community, and the environment by providing scientific review and oversight to human subjects and laboratory biological research at PIBC institutions.
Recombinant or synthetic nucleic acid molecules uses: cells expressing foreign genes such as GFP or other genes of interest, viral vectors, viruses or microorganisms that contain or express foreign genes, generation of transgenic animals, plants, insects or nematodes, using the CRISPR/Cas system, or other uses as described in the NIH Guidelines.
Biological agents: pathogenic and non-pathogenic microorganisms.
Human or non-human primate (NHP) materials: unfixed tissues, cells and cell lines, and fluids such as blood or blood products from humans or non-human primates.
Select agent toxins as listed here.
Recombinant or synthetic nucleic acid molecules used in human gene transfer (i.e., gene therapy) or vaccines to elicit an immune response.
Biological agents: pathogenic and non-pathogenic microorganisms including live vaccine strains.
Xenotransplantation or Xenografts: Xenotransplantation involves the transplantation, implantation or infusion of live cells, tissues, or organs from a nonhuman animal source or human body fluids, cells, tissues, or organs that have had ex vivo contact with live nonhuman animal cells, tissues, or organs.
Xenografts are when tissue or organs from an individual of one species is transplanted into or grafted onto an organism of another species, genus, or family such as use of pig heart valves in humans.
Ryan Schlimgen, Ph.D. Director of the Partners Institutional Biosafety Committee email@example.com 857-282-1799
Danielle Morin PIBC Coordinatordmorin3@partners.org 857-282-1798